Form 8-K

8-K — Sana Biotechnology, Inc.

Accession: 0001193125-26-384405

Filed: 2026-09-08

Period: 2026-09-08

CIK: 0001770121

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — d170343d8k.htm (Primary)

EX-99.1 (d170343dex991.htm)

GRAPHIC (g170343ex99_1s10g1.jpg)

GRAPHIC (g170343ex99_1s11g1.jpg)

GRAPHIC (g170343ex99_1s12g1.jpg)

GRAPHIC (g170343ex99_1s13g1.jpg)

GRAPHIC (g170343ex99_1s14g1.jpg)

GRAPHIC (g170343ex99_1s15g1.jpg)

GRAPHIC (g170343ex99_1s16g1.jpg)

GRAPHIC (g170343ex99_1s17g1.jpg)

GRAPHIC (g170343ex99_1s18g1.jpg)

GRAPHIC (g170343ex99_1s19g1.jpg)

GRAPHIC (g170343ex99_1s1g1.jpg)

GRAPHIC (g170343ex99_1s20g1.jpg)

GRAPHIC (g170343ex99_1s21g1.jpg)

GRAPHIC (g170343ex99_1s22g1.jpg)

GRAPHIC (g170343ex99_1s23g1.jpg)

GRAPHIC (g170343ex99_1s24g1.jpg)

GRAPHIC (g170343ex99_1s25g1.jpg)

GRAPHIC (g170343ex99_1s26g1.jpg)

GRAPHIC (g170343ex99_1s27g1.jpg)

GRAPHIC (g170343ex99_1s28g1.jpg)

GRAPHIC (g170343ex99_1s29g1.jpg)

GRAPHIC (g170343ex99_1s2g1.jpg)

GRAPHIC (g170343ex99_1s3g1.jpg)

GRAPHIC (g170343ex99_1s4g1.jpg)

GRAPHIC (g170343ex99_1s5g1.jpg)

GRAPHIC (g170343ex99_1s6g1.jpg)

GRAPHIC (g170343ex99_1s7g1.jpg)

GRAPHIC (g170343ex99_1s8g1.jpg)

GRAPHIC (g170343ex99_1s9g1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d170343d8k.htm · Sequence: 1

8-K

false 0001770121 0001770121 2026-09-08 2026-09-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 8, 2026

SANA BIOTECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-39941

83-1381173

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification Number)

188 East Blaine Street, Suite 350

Seattle, Washington 98102

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (206) 701-7914

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share

SANA

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD Disclosure.

On September 8, 2026, Sana Biotechnology, Inc. (the “Company”) released an updated corporate presentation (the “Corporate Presentation”), which it intends to discuss at investor conferences. A copy of the Corporate Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated by reference herein.

By furnishing the information in this Item 7.01 of this Current Report, including Exhibit 99.1, the Company makes no admission as to the materiality of such information. The information contained herein is intended to be considered in the context of the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) and other public announcements that the Company makes, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the Corporate Presentation, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

In accordance with General Instruction B.2 of Form 8-K, the information furnished with this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

See the Exhibit Index below, which is incorporated by reference herein.

EXHIBIT INDEX

Exhibit

Number

Description

99.1

Corporate Presentation dated September 8, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Sana Biotechnology, Inc.

Date: September 8, 2026

By:

/s/ Aaron M. Grossman

Aaron M. Grossman

Executive Vice President, Chief Legal Officer

EX-99.1

Filename: d170343dex991.htm · Sequence: 2

EX-99.1

Corporate Presentation September 2026

Exhibit 99.1

This presentation contains

forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws. All statements other than statements of historical

facts contained in this presentation, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some

cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,”

“design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,”

“predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of

these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its

financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events.

These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and

results of the Company’s current and future research and development programs, preclinical studies, and clinical trials. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the

risk factors identified in the Company’s SEC reports, including its Quarterly Report on Form 10-Q dated August 10, 2026. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any

reason. Cautionary note regarding forward-looking statements

Type 1 diabetes represents a

significant opportunity with validated biology ~10M people WW live with type 1 diabetes; current standard treatment remains exogenous insulin Disease impact remains significant, and patients want new alternatives Sana has made meaningful

progress over past year toward IND preparedness Collaboration with Mayo Clinic brings capital as well as support in building broad patient delivery model for SC451 2026 goal of filing SC451 IND and starting Phase 1/2 trial Rapid potential

clinical proof of concept with demonstration of immune evasion, beta cell function, and glucose normalization In vivo CAR T cells provide a second potential transformative platform CAR T cells are transformative for many people with blood cancers

and autoimmune diseases, but have clear limitations In vivo CAR T cells have potential for no conditioning chemotherapy, comparable efficacy, off-the-shelf availability In vivo non-human primate (NHP) data: potent CAR T cells with

cell-specific delivery SG293 in non-Hodgkin lymphoma – potential to share first-in-human data in 1H 2027 SG227 in multiple myeloma – expect to begin clinical study as early as 2027 Changing the Possible for Patients Sana

Biotechnology

~10M people WW with T1D; almost

2M in U.S. alone1 Etiology: autoimmune destruction of insulin-producing pancreatic beta cells Insulin replacement therapy is not curative, and patients need something better With the best current care (automated insulin pumps and continuous

glucose monitoring), life expectancy is still a decade shorter Patients and caregivers battle the daily burden to control glucose, short-term hypoglycemia risk, and long-term sequelae of high blood sugars Type 1 diabetes is a significant unmet

need 1T1D Index and the International Diabetes Foundation; 2who.int/diabetes/global-report. Diabetes can damage multiple organs and raise the risk of early death2 Stroke Blindness Heart attack Kidney failure Amputation

T1D is a disease of missing pancreatic

beta cells Advancing toward a cure for broad T1D population Primary islet transplants provide long-term glucose control, but: Supply is an issue Requires chronic immunosuppression 1 Stem-cell derived islets provide a scalable supply, but: Requires

chronic immunosuppression 2 Hypoimmune edits eliminate the need for immunosuppression 3 The Goal A one-time treatment with long-term normal blood glucose without insulin or immunosuppression

Allogeneic cell rejection ~75 years of

transplants – immune rejection remains the largest problem Lifelong immunosuppression is current standard Genome modification efforts to date have generally been incomplete Autologous therapies have limited scalability and are only available

for a small number of cell types Overcoming allogeneic immune rejection has been key limitation in transplant and cellular medicine Abbreviations: MHC, major histocompatibility complex. Sana’s hypoimmune approach + CD47 - MHC I - MHC II

Healthy donor cells Hypoimmune cells Disruption of MHC Class I & II expression Overexpression of CD47 1 2 3 Blocks adaptive immune system Blocks innate immune system

Sana has pioneered hypoimmune

technology

Transplant into T1D patient without

immunosuppression HIP gene modification of islet cells Donor cadaveric islet cells 1 2 3 Safety Immune evasion Cell survival Key Measured Outcomes Allogeneic, primary human HIP islet cell transplantation in type 1 diabetes patient Intramuscular

administration in forearm No immunosuppression Low dose first-in-human safety study Trial performed at Uppsala University Hospital Overview Clinical validation of hypoimmune islet cells in T1D patient without immunosuppression

UP421 continues to evade immune

detection and function without any therapy-related adverse events All primary and secondary endpoints met Endpoints Wk 1 Wk 2 Wk 3 Wk 4 Wk 6 Wk 8 Wk 12 Wk 16/18 Wk 26 Wk 39 Wk 52 Safety (no AE/SAE related to drug) Cell survival/function (C-peptide)

Graft visibility (MRI) Not performed (as per protocol) Not performed (as per protocol) MRI & PET-MRI Not performed (as per protocol) MRI & PET-MRI Adaptive immune evasion Innate immune evasion

Basal C-peptide in peripheral blood

HIP islet cell survival and function through 14 months Baseline: Below limit of detection (LOD).Sensitivity: 0.48 pmol/L. Dots represent technical triplicates. C-peptide analyzed in serum. Abbreviations: MMTT, mixed meal tolerance test. Increase in

C-peptide levels in the MMTT

Week 12 Week 52 Week 12 and 52

PET/MRI: further evidence of graft survival MR T2-STIR-weighted trans images showing signal in m. brachioradialis after injection of UP421 Uptake of Exendin-4 tracer specific for GLP-1R positive cells Graft Muscle Abbreviations: GLP-1R,

glucagon-like peptide-1 receptor; m, musculus; PET-MRI, positron emission tomography–magnetic resonance imaging; SUV, standardized uptake value.

Wild-type cells Result: cell

killing MHC Class I/II K/O cells Result: cell killing Fully HIP-modified cells: Result: no cell killing No detectable immune response toward HIP islet cells at 12 months Abbreviation: PBMC, peripheral blood mononuclear cells; K/O, knock-out Summary:

No killing of HIP-modified UP421 cell population by PBMC and serum Assay tests patient immune cells (PBMCs) plus serum (antibodies plus complement) against various cell populations from UP421 drug product Month 9 Month 12 Month 9 Month 12 Month 9

Month 12 Baseline Month 6 Baseline Month 6 Baseline Month 6 No Killing Killing Killing Killing Killing Killing Killing Killing No Killing No Killing No Killing No Killing Normalized cell index Hours Hours Hours + CD47 MHC I MHC II + CD47 MHC I MHC

II + CD47 MHC I MHC II

SC451: developing for the broad T1D

population Make hypoimmune islet cells from stem cells 1 Manufacture at scale 2 Deliver as a one-time therapy 3 SC451 program – HIP stem cell-derived islet cell therapy delivered with no immunosuppression Goal is to file IND and begin

Phase 1/2 trial this year Intramuscular delivery + CD47 MHC I MHC II Safety Switch + CD47 MHC I MHC II Safety Switch

01. Nonclinical package

Comprehensive nonclinical testing started and nearing completion 03. Regulatory Dialogues with global regulators 02. Manufacturing Completed GMP master cell bank and working cell bank production Tech transfer to CDMOs ongoing Scale-up work 04.

Clinical planning Clinical sites selected and activation activities have begun Defined target population for clinical trial SC451 We made significant progress in the last 18 months in turning this exciting science into a medicine

SC451: next steps for value

creation Complete GLP toxicology study & non-clinical testing package Complete GMP tech transfer & manufacture clinical trial material File IND and equivalent in at least one other geography Begin Phase 1 testing Make significant progress on

commercial scale manufacturing process

Early immune evasion Endogenous

insulin production evident within first month Potential for insulin independence within 3-6 months SC451 Phase 1/2 has clear definitions of success: safety, cell survival, and function D7 D0 D28 SC451 transplantation Up to Y5 Y2 M12 Active follow-up

(year 1) Active follow-up (year 2) Active follow-up (years 3, 4, 5)

Fusosome technology: cell-specific

in vivo delivery F G Fusosome Sana approach: Leverage insights from nature to deliver various payloads to specific cells without lymphodepletion

Target cell killing CAR T cell

amplification Delivery Transduction of CD8 T cells Expression Transgene integration & CAR expression Function Targeted cell killing T cell Fusosome B cell/tumor CAR T cell Transgene for CAR expression CAR CAR Sana is pursuing in vivo engineering

of CAR T cells using a fusosome vector system Potential to make better CAR T cells Eliminates conditioning chemotherapy Simplifies manufacturing

Lowers risk of off-target toxicity

Lowers immunogenicity risk, potentially improving safety, persistence, and ability to re-dose Improves manufacturability CAR T cells typically undergo multi-logarithmic expansion inside the patient in order to clear target cells Integrated

DNA replicates with cell division; mRNA does not Sana made two critical assumptions in developing this program Cell specificity of delivery will be important Integration into T cell DNA is important

Fusogen has cross-reactivity with

NHP CD8 CD19 CAR does not cross react with NHP CD19 Therefore, excellent model for PK, but not PD 4 NHP at each dose received single injection GLP Tox Study: SG299 leads to potent transduction of circulating CD8+ cells (~15-20%) Potent

transduction of circulating CD8+ T cells Abbreviations: LOD, limit of detection; LOQ, limit of quantification; PK, pharmacokinetics; PD, pharmacodynamics.

4 NHP at each dose received single

injection GLP Tox Study: SG299 is specific for CD8+ cells; no transduction detected in hepatocytes or gonadal tissue NO LIVER OFF-TARGET NO TESTIS OFF-TARGET VCN is a sensitive marker for transduction Abbreviations: VCN, vector copy

number.

CD8 T cell transduction with high

on-target specificity T cell restriction factors identified as limiting potency in resting T cells Next generation: Improved the platform to increase potency and probability of success Potent transduction of resting T cells in vivo resulting

in CAR T cells that expand and deplete B cells without lymphodepletion Overcome restriction via novel compositions Minimize CAR surface expression to decrease immunogenicity risk Where we were: What we did: Where we are now:

SG293 and SG227: next generation in

vivo CAR Ts with improved potency and manufacturability SG293 Novel fusogen to increase gene delivery and reduce dose, while maintaining high specificity 1 Reduced CAR on vector particle to reduce immunogenicity and improve manufacturability 2

Incorporates an activation factor on the vector to increase CAR T cell expansion and function 3 CD3 Fusogen anti-CD8 binder CAR 1 2 CD19 BCMA SG227 3

SG293 incorporates novel

fusogen with high specificity in vitro SG293 shows specificity for on-target vs. off-target cells in vitro compared to targeted VSV-G fusogen Cell Lines ON-target (CD8+)à Low phagocytic activity High phagocytic activity

NHP study explored the efficacy,

tolerability, and biodistribution of SG293 surrogate in vivo D-14 Multiple timepoints Necropsy (liver, spleen, etc.) Vehicle or Fusosome delivery (IV) In-process testing Pre-study baseline D0 D56 Study assessment overview General safety endpoints

Clinical observations Body weight and temperature measurements Clinical pathology Neurological assessment CAR+ T cells in circulation B cells in circulation Lymph node biopsy (Day 21) Necropsy (Day 56)

Significant in vivo biologic

activity demonstrated in NHP with SG293 surrogate BLQ: Below limit of quantitation Significant CAR T expansion in the blood Complete depletion of circulating B cells Lymph nodes at Week 3 Evidence of “reset” when B cells return Vec Ctrl

NHP1 NHP2 Control NHP1 NHP2 Double negative (IgD-/CD27-) Naïve (IgD+/CD27-) Unswitched Mem (IgD+/CD27+) Switched Mem (IgD-/CD27+) Transitional (CD10+) NHP1 NHP2 Controls

Sana’s fusogen platform has

the potential for multiple best-in-class therapies First SG293 trial for patients with non-Hodgkin lymphoma With early safety and efficacy data, potential to move rapidly into autoimmune disease with SG293 and multiple myeloma with SG227

Recent progress creates potential for best-in-class in vivo CAR T cell platform Platform can be readily expanded to other targets

Type 1 diabetes: a disease in need

of better alternatives Scientific validation that a functional cure is possible SC451 assembles all components into a scalable platform 2026: Goal is to file IND & start Phase 1/2 trial Potential for early clinical proof of concept: Immune

evasion Endogenous insulin production Glucose control without exogenous insulin Fusogen platform has potential for best-in-class profile for multiple therapies SG293: potential first-in-human NHL data SG227: potential to begin clinical study in

multiple myeloma Sana: next 12 months can be transformative

GRAPHIC

Filename: g170343ex99_1s10g1.jpg · Sequence: 6

Binary file (78225 bytes)

Download g170343ex99_1s10g1.jpg

GRAPHIC

Filename: g170343ex99_1s11g1.jpg · Sequence: 7

Binary file (77591 bytes)

Download g170343ex99_1s11g1.jpg

GRAPHIC

Filename: g170343ex99_1s12g1.jpg · Sequence: 8

Binary file (127954 bytes)

Download g170343ex99_1s12g1.jpg

GRAPHIC

Filename: g170343ex99_1s13g1.jpg · Sequence: 9

Binary file (85383 bytes)

Download g170343ex99_1s13g1.jpg

GRAPHIC

Filename: g170343ex99_1s14g1.jpg · Sequence: 10

Binary file (85031 bytes)

Download g170343ex99_1s14g1.jpg

GRAPHIC

Filename: g170343ex99_1s15g1.jpg · Sequence: 11

Binary file (60793 bytes)

Download g170343ex99_1s15g1.jpg

GRAPHIC

Filename: g170343ex99_1s16g1.jpg · Sequence: 12

Binary file (63126 bytes)

Download g170343ex99_1s16g1.jpg

GRAPHIC

Filename: g170343ex99_1s17g1.jpg · Sequence: 13

Binary file (65248 bytes)

Download g170343ex99_1s17g1.jpg

GRAPHIC

Filename: g170343ex99_1s18g1.jpg · Sequence: 14

Binary file (93539 bytes)

Download g170343ex99_1s18g1.jpg

GRAPHIC

Filename: g170343ex99_1s19g1.jpg · Sequence: 15

Binary file (78562 bytes)

Download g170343ex99_1s19g1.jpg

GRAPHIC

Filename: g170343ex99_1s1g1.jpg · Sequence: 16

Binary file (31750 bytes)

Download g170343ex99_1s1g1.jpg

GRAPHIC

Filename: g170343ex99_1s20g1.jpg · Sequence: 17

Binary file (75268 bytes)

Download g170343ex99_1s20g1.jpg

GRAPHIC

Filename: g170343ex99_1s21g1.jpg · Sequence: 18

Binary file (74717 bytes)

Download g170343ex99_1s21g1.jpg

GRAPHIC

Filename: g170343ex99_1s22g1.jpg · Sequence: 19

Binary file (85584 bytes)

Download g170343ex99_1s22g1.jpg

GRAPHIC

Filename: g170343ex99_1s23g1.jpg · Sequence: 20

Binary file (84117 bytes)

Download g170343ex99_1s23g1.jpg

GRAPHIC

Filename: g170343ex99_1s24g1.jpg · Sequence: 21

Binary file (102870 bytes)

Download g170343ex99_1s24g1.jpg

GRAPHIC

Filename: g170343ex99_1s25g1.jpg · Sequence: 22

Binary file (69147 bytes)

Download g170343ex99_1s25g1.jpg

GRAPHIC

Filename: g170343ex99_1s26g1.jpg · Sequence: 23

Binary file (109044 bytes)

Download g170343ex99_1s26g1.jpg

GRAPHIC

Filename: g170343ex99_1s27g1.jpg · Sequence: 24

Binary file (71433 bytes)

Download g170343ex99_1s27g1.jpg

GRAPHIC

Filename: g170343ex99_1s28g1.jpg · Sequence: 25

Binary file (79787 bytes)

Download g170343ex99_1s28g1.jpg

GRAPHIC

Filename: g170343ex99_1s29g1.jpg · Sequence: 26

Binary file (26382 bytes)

Download g170343ex99_1s29g1.jpg

GRAPHIC

Filename: g170343ex99_1s2g1.jpg · Sequence: 27

Binary file (159471 bytes)

Download g170343ex99_1s2g1.jpg

GRAPHIC

Filename: g170343ex99_1s3g1.jpg · Sequence: 28

Binary file (124979 bytes)

Download g170343ex99_1s3g1.jpg

GRAPHIC

Filename: g170343ex99_1s4g1.jpg · Sequence: 29

Binary file (87357 bytes)

Download g170343ex99_1s4g1.jpg

GRAPHIC

Filename: g170343ex99_1s5g1.jpg · Sequence: 30

Binary file (89018 bytes)

Download g170343ex99_1s5g1.jpg

GRAPHIC

Filename: g170343ex99_1s6g1.jpg · Sequence: 31

Binary file (93393 bytes)

Download g170343ex99_1s6g1.jpg

GRAPHIC

Filename: g170343ex99_1s7g1.jpg · Sequence: 32

Binary file (132040 bytes)

Download g170343ex99_1s7g1.jpg

GRAPHIC

Filename: g170343ex99_1s8g1.jpg · Sequence: 33

Binary file (86701 bytes)

Download g170343ex99_1s8g1.jpg

GRAPHIC

Filename: g170343ex99_1s9g1.jpg · Sequence: 34

Binary file (107231 bytes)

Download g170343ex99_1s9g1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 36

v3.26.1

Document and Entity Information

Sep. 08, 2026

Cover [Abstract]

Amendment Flag

false

Entity Central Index Key

0001770121

Document Type

8-K

Document Period End Date

Sep. 08, 2026

Entity Registrant Name

SANA BIOTECHNOLOGY, INC.

Entity Incorporation State Country Code

Entity File Number

001-39941

Entity Tax Identification Number

83-1381173

Entity Address, Address Line One

188 East Blaine Street

Entity Address, Address Line Two

Suite 350

Entity Address, City or Town

Seattle

Entity Address, State or Province

Entity Address, Postal Zip Code

98102

City Area Code

(206)

Local Phone Number

701-7914

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Security 12b Title

Common Stock, $0.0001 par value per share

Trading Symbol

SANA

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Entity Ex Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration